All studies

T2D photo_spacer-03.jpgReal-world treatment patterns associated with new antidiabetic drug provide insights on clinician efforts to optimize type 2 diabetes (T2D) therapy



Once-weekly semaglutide (Ozempic; sema OW) is being initiated further down the T2D treatment pathway and predominantly being used as an add-on therapy to existing antidiabetic medications. It seems to help some patients decrease their overall T2D medications.

Enterprise Analytics Hub domain(s): quality of care, CarelonRx

Summary

Background
Anti-diabetic medication treatment patterns often differ based on a variety of patient and prescriber factors. Understanding these patterns may provide insight on optimizing therapy, especially when considering initiation of a new therapy. This study presents real-world evidence on T2D treatment patterns associated with sema OW initiation within a large cohort of T2D patients.

Methods

Virtual registry of sema OW users using administrative data.


Results

  • Our study found that since approval in 2017, sema OW was typically started further down the T2D treatment pathway and predominantly as add-on therapy to existing antidiabetics.
    • At the time of sema OW initiation, 60% of patients were on at least two antidiabetic medications and 30% were on at least three antidiabetic medications.
  • Approximately one third of patients were able to decrease their overall T2D medication use after sema OW initiation and evaluation of HbA1c (average blood sugar) level.
  • HbA1c reduction in real-world practice was similar to HbA1c reduction observed in clinical trials.

T2D Figure.jpg


Key takeaways
This information presents several opportunities for Elevance Health to improve the care of their members with T2D:

  • Assess the impact of programs promoting the initiation of semaglutide/similar medications earlier in the T2D treatment pathway, especially in patients with comorbid cardiovascular and chronic kidney disease, to align with current clinical guidelines.
  • In light of recent FDA approval of semaglutide (Wegovy, 2.4mg once weekly) to treat obesity (by reducing weight), this may present an opportunity to health plans to optimize care coordination for members with T2D and obesity.


Publications

Visaria J, Uzoigwe C, Swift C, Dang-Tan T, Paprocki Y, Willey VJ. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population. Clin Ther. 2021. May;43(5):808-821.

Poster presented at the American Diabetes Association (ADA) Annual Scientific Sessions Conference 2021. Evaluating Anti-Diabetic Medication Treatment Patterns in T2D Patients Initiating Once-Weekly Semaglutide (sema OW)


Additional and relevant publications

Poster presented at the American Diabetes Association (ADA) Annual Scientific Sessions Conference 2021. Real-World Evaluation of Once-Weekly Semaglutide (sema OW) in Patients Newly Initiating GLP-1 Agonist Therapy

Poster presented at the American Diabetes Association (ADA) Annual Scientific Sessions Conference 2021. Real-World Effectiveness of Once-Weekly Semaglutide (sema OW) from a US Commercially Insured and Medicare Advantage Population

Poster presented at the American Diabetes Association (ADA) Annual Scientific Sessions Conference 2021.  Real-World Effectiveness of Oral Semaglutide (OS) from a US Commercially Insured and Medicare Advantage Population

Poster presented at the American Diabetes Association (ADA) Annual Scientific Sessions Conference 2020. Real-World Effectiveness of Once-Weekly Semaglutide from a US Commercially Insured and Medicare Advantage Population

Poster presented at the American Diabetes Association (ADA) Annual Scientific Sessions Conference 2019. Real-World Effectiveness of Semaglutide in Early Users from a US Commercially Insured and Medicare Advantage Population

Carelon Research project team: Vince Willey, Nitin Shivappa*, Jason Tan, Puneet Singh
*Carelon Research Associate at the time of the study. 


For more information on a specific study or to connect with the Actionable Insights Committee, contact us at [email protected].

This study was conducted by Carelon Research (formerly HealthCore, Inc.), a subsidiary of Elevance Health and funded by Novo Nordisk. Dissemination and sharing of the Newsletter is limited to Elevance Health and its subsidiaries and included findings and implications are for Elevance Health and its affiliates’ internal use only.


Ready to get started? Sign up now!

Lorem ipsum dolor sit amet

2-Col, Right Image

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut.

Lorem ipsum dolor sit amet, consectetur adipisicing, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut. Ut ad minim veniam.

Vestibulum ante ipsum primis in faucibus orci luctus etel ultrices posuere cubilia Curae.

2-Col, Left Image

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut.

  • Many addon features
  • Fully responsive & adaptive
  • SEO optimized
  • Attractive with a modern touch
  • Full Support

Ut Enim Minima

Sed ut perspiciatis unde omnis iste natus error sit voluptatem!

Quis Autem Vel

Nemo enim ipsam voluptatem quia voluptas sit odit aut fugit!

Quo Voluptas

Ut enim ad minima veniam, quis nostrum exercitationem ullam!

Carelon Research researchers develop pregnancy algorithm critical for maternal and infant health outcomes research

This algorithm will assist Carelon Research and Elevance Health in assessing drug safety during pregnancy, developing best practices...

Real-world evidence supports NCCN guidelines recommending against first-line use of chemoimmunotherapy (CIT) in high-risk CLL/SLL patients

First-line use of CIT for patients with genetic abnormalities in CLL/SLL, a cancer of the blood and bone marrow...

Consectetur adipiscing elit...

Joanna C.

"Et harum quidem rerum facilis est et expedita distinctio!"

Stanley T.

"Nam libero tempore, cum soluta nobis est eligendi."

Danielle W.

"Temporibus autem quibusdam et aut officiis debitis!"

Teams at Carelon Research

The clinical research team at Carelon Research coordinates and conducts a broad range of clinical trials and registries – from small studies focused on rare and orphan diseases to large studies of complex and chronic conditions. We work with projects across the research spectrum, including life sciences, biotech, medical device, diagnostics, the government (National Institutes of Health, CDC, etc.) and academic institutions. For more information, visit our clinical research page.
The business development and marketing and communications experts at Carelon Research work with external clients and internal subject matter experts to develop a variety of research projects and disseminate results via conferences and digital marketing platforms including email and social media.
The HEOR team at Carelon Research develops study designs, translates value stories, and facilitates payer collaborations. Our researchers generate evidence of the real-world value of biomedical products and translate that evidence into actionable information for stakeholders. For more information, visit our health economics and outcomes research page.
The research operations team at Carelon Research focuses on improving the efficiency, effectiveness, and profitability of business performance and operations. The team includes the project and program management team, operational leaders focused on ensuring program/project goals are met according to plan, schedule, and scope; the data management team, specializing in the application of techniques to access, collect, integrate, cleanse, govern, store, and prepare data for analytics and ensures the body of data at Carelon Research is accurate and consistent, accessible, and properly secured; and the data analytics team of biostatisticians and analysts provide advanced analytic expertise and programming capabilities to lead and support the company’s scientific portfolio of database and clinical research.
The safety & epidemiology research team at Carelon Research uncovers vital evidence on the utilization, safety, and effectiveness of biopharmaceuticals and devices in large, real-world patient populations. Our researchers provide a broad range of expertise and operational experience to the timely and accurate execution of epidemiologic studies in the pre- and post-marketing settings. For more information, visit our safety and epidemiology research page.